| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. | Director | Ordinary Shares | 1.49M | $26.7M | $18.01 | Oct 21, 2022 | Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd |
| Keros Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 155K | $2.24M | $14.44 | Jun 4, 2025 | Indirect |
| LB PHARMACEUTICALS INC | Director | Common Stock | 1.41M | Sep 12, 2025 | Indirect | ||
| LB PHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 22.4K | Sep 10, 2025 | Direct | ||
| Eloxx Pharmaceuticals, Inc. | Director | Stock Options (Right to Buy) | 20K | Jun 15, 2022 | Direct | ||
| Keros Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 10.5K | Jun 4, 2025 | Direct | ||
| LB PHARMACEUTICALS INC | Director | Series C Preferred Stock | 0 | Sep 12, 2025 | Indirect | ||
| UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | Oct 21, 2022 | By Pontifax Cayman III Limited Partnership | ||
| UroGen Pharma Ltd. | Director | Stock Option (right to buy) | 0 | Oct 21, 2022 | By Pontifax (Israel) III Limited Partnership |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | Sep 12, 2025 | 3 | $15M | 4 | Sep 16, 2025 | Director |
| LBRX | LB PHARMACEUTICALS INC | Sep 10, 2025 | 1 | $0 | 4 | Sep 12, 2025 | Director |
| LBRX | LB PHARMACEUTICALS INC | Sep 10, 2025 | 0 | $0 | 3 | Sep 11, 2025 | Director, 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Jun 4, 2025 | 0 | $0 | 4/A | Jun 11, 2025 | Director, 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | May 30, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director, 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Nov 29, 2022 | 6 | -$1 | 4 | Nov 30, 2022 | Director, 10%+ Owner |
| URGN | UroGen Pharma Ltd. | Oct 21, 2022 | 3 | $285K | 4/A | Feb 28, 2023 | Director |
| URGN | UroGen Pharma Ltd. | Jun 16, 2022 | 2 | $11.1K | 4 | Feb 28, 2023 | Director |
| ELOX | Eloxx Pharmaceuticals, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
| URGN | UroGen Pharma Ltd. | Jun 8, 2022 | 2 | $0 | 4 | Jun 10, 2022 | Director |
| URGN | UroGen Pharma Ltd. | Jun 6, 2022 | 2 | $5.15K | 4/A | Feb 28, 2023 | Director |
| KROS | Keros Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director, 10%+ Owner |
| KROS | Keros Therapeutics, Inc. | Jun 1, 2021 | 1 | $0 | 4 | Jun 3, 2021 | Director, 10%+ Owner |
| ELOX | Eloxx Pharmaceuticals, Inc. | May 19, 2021 | 1 | $0 | 4 | May 20, 2021 | Director |
| ELOX | Eloxx Pharmaceuticals, Inc. | May 13, 2021 | 4 | $8M | 4 | May 17, 2021 | Director |
| URGN | UroGen Pharma Ltd. | Mar 25, 2021 | 2 | $5.15K | 4/A | Jun 9, 2021 | Director |
| URGN | UroGen Pharma Ltd. | Mar 25, 2021 | 4 | $11.1K | 4 | Jun 9, 2021 | Director |
| KROS | Keros Therapeutics, Inc. | Apr 7, 2020 | 0 | $0 | 3/A | Nov 30, 2022 | Director, 10%+ Owner |